Biotech / Life Science Sector

Transcription

1 Trends in the Canadian and UK Biotech / Life Science Sector Dr. Patrik Frei December 2012 London

2 Venture Valuation Mission Independent assessment and valuation of technology driven companies / products in growth industries Life Sciences Database Biotechgate: Offices Employees Clients HQ: Zurich with representative offices in North America, Europe and Asia (Seoul) 6 people in Switzerland, 8 representatives, JV in India Pharma, Biotech and Investors such as Novartis Venture Fund, GSK, European Investment Bank, 4SC, Arpida/Evolva, Celtic Pharma

3 Biotechgate Subscription based Database with company profiles in over 70 countries products licensing opportunities licensing deals Global Life Sciences Database to map clusters / countries 28 country databases Life Sciences statistics Membership / Regional Directory 3

4 Global Partners 4

5 Biotech numbers United Kingdom 624 Total Biotechnology Companies Biotech - Therapeutics Biotech R&D Services Biotech - Other % Percentage of SME's 90% 7% Percentage of Companies Publicly Owned 14% USD 517 M Financing / Capital Raised in 2012 (Public and Private) USD 181 M 302 Licensing Opportunities 204

6 Geography United Kingdom

7 Companies Per Cluster: L-C and 200 Bi iotech Companies per Cluster Cluster

8 Companies by Sector Biotechnology Companies in the U.K Breakdown on subcategory based on 1057 entries by 624 companies Bioinformatics and Bioelectronics 4% AgroBio 2% Therapeutics 16% Contract Research and Manufacturing 18% Other Services and Suppliers 26% Diagnostics and Analytical Services 22% Biotechnology Companies in Breakdown on subcategory based on 1018 entries by 629 companies Drug Delivery 5% AgroBio 9% Veterinary 5% Therapeutics 16% Contract Research & Manufacturing 11% Environment 13% Diagnostics and Analytical Services 13% Genomics and Proteomics 7% Other Services Food and and Suppliers Nutraceuticals 21% 7% Industrial Biotechnology 5%

9 Size of companies Size of Biotechnology Companies in the U.K (by number of employees) 1-10: 27% Size of Biotechnology Companies in (by number of employees) % : 22% 11-50: 36% % % 1-10: 20% 11-50: 50%

10 Ownership Public, Private and Subsidiary Companies in the U.K Public 6% Subsidiary 19% Private / independent 75% Public, Private and Subsidiary Companies in Subsidiary 10% Public 14% Private / independent 76%

11 Companies Founded No. of Companies Founded UK Year

12 Sources of Foundation Company Source of Foundation in the U.K Independent foundation 36% Undisclosed 28% Management buyout (MBO) 1% Other 3% Merger 1% Spin-off from company 2% Spin-off from public institution / NPO 2% Spin-off from university 11% Subsidiary 16% Company Source of Foundation in Independent foundation 48% Merger 1% Spin-off from company 1% Undisclosed 31% Other 3% Spin-off from public institution / NPO 1% Spin-off from university 5% Subsidiary 10%

13 Financing Biotech Therapeutic Financing Rounds Number of Financing Rounds Total Value in Million USD Financing Value UK ($) Financing Value ($) No. of Rounds No. of Rounds UK

14 Top 5 Financings 2012 Top 5 Largest Financings 2012 (Public/Private) USD Millions United Kingdom Circassia Ltd YM Biosciences* Cell Medica Thrasos Therapeutics PsiOxis Therapeutics Resverlogix Corp* F2G Ltd Zymeworks Inc ReNeuron Group Plc* 16 7 Lorus Therapeutics* * Denotes Public Company

15 Product pipeline Biotechnology Pipeline Preclinical Phase I Phase II Ph hase III UK UK UK UK Number of Products

16 Product pipeline Pipeline Indications other Injury, poisoning and certain other consequences of external causes Diseases of the eye Diseases of the blood and blood-forming organs; immune disorders Mental and behavioural disorders Digestive system Skin and subcutaneous tissue Respiratory Genitourinary system Musculoskeletal system and connective tissue UK Diseases of the nervous system Infectious and parasitic diseases Cardiovascular Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified Neoplasms / cancer / oncology Endocrine, nutritional and metabolic diseases Number of Products

17 Thank you for listening! Slides available on Tel.: +41 (43) Venture Valuation AG Fax: +41 (43) Kasernenstrasse Zürich Switzerland